Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly report beat expectations and raised its full-year outlook, but the stocks reaction was muted and volatile. Traders are weighing strong AI-computing demand against heavy capital spending, debt and interest costs, and potential dilution.

NVIDIA is under pressure as a board investigation into CEO Jensen Huangs admitted affair with an executive at a customer brings scrutiny over possible disclosure, national-security and export-control risks; claims that the executive was linked to Chinese intelligence remain unproven. Traders are split between treating the selloff as a buying opportunity because they see the business as intact and worrying about legal or regulatory fallout and a possible CEO departure.

Netlists Q3 results are driving attention, with traders highlighting sharply improved gross margins and profitability from Samsung licensing revenue and stronger product margins. The reaction is broadly upbeat, but investors are debating the steep sequential drop in product sales and whether it signals reduced SK hynix supply; Micron licensing revenue expected in Q4 is seen as a possible offset.

Amprius quarterly results are driving attention: revenue growth and raised full-year guidance were offset by an EPS miss and negative adjusted EBITDA, prompting a sharp selloff despite many traders calling the report strong. The community is split between viewing the drop as a reaction to profitability concerns and blaming broader market weakness or short-selling.

Rigettis quarterly results missed expectations, prompting concern about weak commercial revenue and ongoing losses. Traders are split between skepticism that its quantum technology can translate into a viable business and optimism about its 108-qubit fidelity milestone and long-term potential.

A Q3 earnings beat, sizable backlog and positive revenue outlook are driving attention, alongside Fireflys Synspective multi-launch agreement. Traders see contract growth as a bullish sign but remain concerned about cash burn and launch execution, with some frustrated by the muted share reaction to the results.

Nebius is drawing attention ahead of its quarterly report, with traders treating CoreWeaves strong results and raised guidance as a read-through for AI-cloud demand while debating whether NBIS can turn demand into revenue without financing or capacity-execution problems. Bulls expect a rebound across neoclouds, while skeptics point to the recent selloff and ongoing concerns about capital needs and whether good results are already priced in.

The scheduled Nov. 22 FDA decision on Capricors Duchenne muscular dystrophy treatment Deramiocel dominates discussion, with traders weighing the HOPE-3 upper-limb results and recent AHA recognition against concerns raised during the advisory-panel review. The quarterly update is viewed as secondary; some investors were disappointed by the lack of new detail on FDA discussions, while approval optimism and bearish skepticism fuel debate around the stocks sharp swings.

LightPaths fiscal first-quarter report is driving attention, with strong revenue growth, a record backlog and expanding gross margins drawing praise. Reactions are mixed: some traders see the results as validation of the growth story, while others point to weak after-hours trading and want clearer evidence of execution and outlook from management.

Kuras Q3 update is drawing attention for accelerating KOMZIFTI uptake, with prescriptions growing faster than new patient startsa sign some traders interpret as improving patient retention and launch traction. The reaction is broadly encouraged by the commercial progress and cash runway, though competition in AML and skepticism about whether early uptake will translate into sustained growth remain part of the debate.